Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Vascular Solutions Gets Clearance for Tumor Treating Gel-Block

November 25, 2014 9:44 am | News | Comments

Vascular Solutions gets clearance from the FDA for tumor treating gel blocks. Read more...                             

TOPICS:

Genetic Test Unlocks Cause of Brisbane Boy's Rare Disease

November 25, 2014 9:24 am | News | Comments

Queensland researchers have led an international effort to uncover the gene behind a young Brisbane boy’s rare developmental condition. Read more...                   

TOPICS:

Researchers Identify New Ways to Drain Cancer's 'Fuel Tank'

November 25, 2014 9:07 am | News | Comments

Scientists at the University of Manchester have discovered a potential weakness in cancer’s ability to return or become resistant to treatment. Read more...                  

TOPICS:
Advertisement

Mali Confirms Eighth Ebola Case

November 25, 2014 8:59 am | News | Comments

Mali has confirmed a new case of Ebola, bringing to eight the number of people who have fallen ill with the deadly disease in the West African country. Read more...                

TOPICS:

Exciting Gains in Fighting Breast Cancer Hormone-Therapy Resistance

November 25, 2014 8:55 am | by Cynthia Fox, Science Editor | Articles | Comments

Guided by breakthrough research on the Estrogen Receptor 1 (ESR1) gene, many researchers and pharmaceutical companies are in hot pursuit of the next big anti-resistance breast cancer drug. Read more...                 

TOPICS:

Researchers Seek New Regulations for Digital Pharma Marketing

November 24, 2014 2:22 pm | by Ryan Bushey, Associate Editor | Articles | Comments

The researchers feel that the current policies for pharmaceutical marketing need to be updated as soon as possible. Read more...                      

TOPICS:

Improving The Odds of Beating Opioids

November 24, 2014 1:16 pm | by Sue McGreevy, Harvard University | News | Comments

Research indicates that live-in programs may result in higher levels of abstinence than the outpatient treatment that is currently the standard of care. Read more...                

TOPICS:

BMS to Collaborate on Immunotherapy Evaluation

November 24, 2014 1:01 pm | News | Comments

BMS and Five Prime Therapeutics Inc. announced that they have entered into an exclusive clinical collaboration agreement to evaluate the safety, tolerability and preliminary efficacy of immunotherapy drugs. Read more...       

TOPICS:
Advertisement

BioMarin Pharma Offers About $680M for Prosensa

November 24, 2014 12:41 pm | News | Comments

The company also said it will make two approximately $80 million milestone payments to Prosensa shareholders. Read more...                       

TOPICS:

New Drugs from Fish Oil Could Aid Artery Repair

November 24, 2014 12:33 pm | by Kathleen Masterson, University of California San Francisco | News | Comments

A common class of naturally occurring molecules from fish oil could help with artery repair. Read more...                         

TOPICS:

Children's Relentless Seizures Halted By New Drug

November 24, 2014 12:22 pm | by Marla Paul, Northwestern University | News | Comments

An investigational medication has been found to effectively treat children with life-threatening and difficult-to-control epileptic seizures without side effects. Read more...              

TOPICS:

Amgen-Sponsored Gastric Cancer Studies Terminated

November 24, 2014 11:01 am | News | Comments

Amgen announced the termination of all Amgen-sponsored clinical studies of rilotumumab in advanced gastric cancer,  including the Phase 3 RILOMET-1 and RILOMET-2 studies. Read more...                                 

TOPICS:

Merck, NewLink Genetics To Collaborate for Ebola Vaccine

November 24, 2014 10:45 am | News | Comments

Merck, known as MSD outside the United States and Canada, and NewLink Genetics Corporation, announced that they have entered into an exclusive worldwide license agreement to research, develop, manufacture, and distribute NewLink’s investigational rVSV-EBOV (Ebola) vaccine candidate. Read more... 

EU Approves Novartis' Signifor Drug for Rare Hormonal Disorder

November 24, 2014 10:38 am | News | Comments

Novartis announced today that the European Commission has approved Signifor (pasireotide) as a new long acting release formulation for once monthly intramuscular injection to treat adult patients with acromegaly for whom surgery is not an option or has not been curative and who are inadequately controlled on treatment with a first-generation somatostatin analogue (SSA).  Read more...

TOPICS:

U.S. Looking Past Ebola to Prepare for Next Outbreak

November 24, 2014 9:25 am | by Lauran Neergaard, AP Medical Writer - Associated Press | News | Comments

The next Ebola or the next SARS. Maybe even the next HIV. Even before the Ebola epidemic in West Africa is brought under control, public health officials are girding for the next health disaster. Read more...                 

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading